NASDAQ:LXRX Lexicon Pharmaceuticals Q3 2026 Earnings Date & Estimates $1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.75 -0.01 (-0.62%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexicon Pharmaceuticals is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Lexicon Pharmaceuticals in Q3 2026Lexicon Pharmaceuticals is expected to post earnings of -$0.06 per share on revenue of $4.15 million. In the same quarter a year earlier Lexicon Pharmaceuticals reported -$0.04 per share on revenue of $14.18 million. Lexicon Pharmaceuticals last reported on August 6, 2026, posting -$0.06 per share and missing the -$0.05 consensus estimate. Lexicon Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.06Expected Revenue$4.15 millionPrior-Year EPS-$0.04Prior-Year Revenue$14.18 millionExpected Revenue Growth-70.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.06 (Missed by -$0.01)Last Quarter Revenue$0.69 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Lexicon Pharmaceuticals Q3 2026 Earnings FAQ When does Lexicon Pharmaceuticals report Q3 2026 earnings? Lexicon Pharmaceuticals (NASDAQ:LXRX) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Lexicon Pharmaceuticals' Q3 2026 earnings call? Lexicon Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Lexicon Pharmaceuticals? Analysts expect Lexicon Pharmaceuticals to post earnings of -$0.06 per share for Q3 2026. How much revenue is Lexicon Pharmaceuticals expected to report? The consensus revenue estimate for Lexicon Pharmaceuticals is $4.15 million for Q3 2026. Lexicon Pharmaceuticals Earnings HeadlinesComparing Puma Biotechnology (NASDAQ:PBYI) & Lexicon Pharmaceuticals (NASDAQ:LXRX)October 6 at 4:29 AM | americanbankingnews.comLexicon Pharmaceuticals consensus price target increased by 17.91% to $4.64October 2, 2026 | msn.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 8 at 1:00 AM | The Oxford Club (Ad)Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial ProgressOctober 2, 2026 | finance.yahoo.comLexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And MoreSeptember 30, 2026 | seekingalpha.comLexicon Pharmaceuticals bondit après une initiation favorable de Cantor FitzgeraldSeptember 29, 2026 | fr.finance.yahoo.comSee More Lexicon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexicon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexicon Pharmaceuticals and other key companies, straight to your email. Email Address About Lexicon PharmaceuticalsLexicon Pharmaceuticals (NASDAQ:LXRX) is a biopharmaceutical company focused on discovering and developing medicines for diseases with significant unmet medical needs. The company uses its expertise in human genetics and gene biology to identify novel drug targets and develop small-molecule therapies. Lexicon’s marketed products include XERMELO (telotristat ethyl), an oral treatment for carcinoid syndrome diarrhea in adults whose symptoms are inadequately controlled by short-acting somatostatin analog therapy. The company also developed INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart-failure visits in certain adults with heart failure and related conditions. Founded in 1995 and headquartered in The Woodlands, Texas, Lexicon has advanced its products through internal research and collaborations with pharmaceutical partners. Its commercial and licensing relationships have supported the availability of its therapies in the United States and selected international markets. Lonnel Coats serves as the company’s president and chief executive officer.View Lexicon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
